Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New York pharma, however, offered the smoothest transaction with the greatest likelihood of success.
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction from the current wholesale acquisition cost of $527.70.
A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big Pharma companies, while smaller biotechs are left to hope “the situation doesn’t get worse.”
Top 25 firm Baker Tilly announced the launch of a new AI platform made specifically for middle market clients, which will be supported and maintained by Baker Tilly professionals over the long term.
Avalara announced a host of new AI capacities that build on its previously announced updates to its product architecture, centering around automation, insights and AI agent integration.
Technical skills will never go away, but there’s a whole other set of leadership and ‘soft’ skills that firms can’t afford to neglect, says Erin Daiber.